Hepatic hemorrhage as a consequence of rapid response to combined targeted therapy in metastatic melanoma

Journal of Surgical Oncology

Volumn 112, Issue 8, 2015, Pages 844-845

  Flaherty, Devin C ^a   Hoffner, Brianna W ^b   Lau, Briana J ^a   Hamid, Omid ^a,b   Faries, Mark B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b Angeles Clinic and Research Institute   (United States)

Author keywords

BRAF; dabrafenib; MEK; trametinib

Indexed keywords

DABRAFENIB; TRAMETINIB; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; OXIME; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ADULT; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; FEMALE; HEMOPERITONEUM; HUMAN; LIVER HEMORRHAGE; LIVER METASTASIS; METASTATIC MELANOMA; MIDDLE AGED; MORBIDITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE; LIVER NEOPLASMS; MELANOMA; PATHOLOGY; SECONDARY; SKIN NEOPLASMS;

ANTINEOPLASTIC AGENTS; FEMALE; HEMOPERITONEUM; HUMANS; IMIDAZOLES; LIVER NEOPLASMS; MELANOMA; MIDDLE AGED; OXIMES; PYRIDONES; PYRIMIDINONES; SKIN NEOPLASMS;

EID: 84955170054     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.24078     Document Type: Article

References (10)

1. Robert C, Karaszewska B, Schachter J, et al.,: Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372: 30-39.
2. Flaherty KT, Infante JR, Daud A, et al.,: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-1703.
3. Long GV, Stroyakovskiy D, Gogas H, et al.,: Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015; 386: 444-451.
4. Waddell JA, Solimando DA, Jr,: Drug monographs: Dabrafenib and trametinib. Hosp Pharm 2013; 48: 818-821.
5. Nosaka T, Hiramatsu K, Nemoto T, et al.,: Ruptured hepatic metastases of cutaneous melanoma during treatment with vemurafenib: An autopsy case report. BMC Clin Pathol 2015; 15: 15.
6. Castellani E, Covarelli P, Boselli C, et al.,: Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib. World J Surg Oncol 2012; 10: 155.
7. Kaye FJ, Ivey AM, Drane WE, et al.,: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma. J Natl Cancer Inst 2015; 107: 378.
8. Lee le M, Feun L, Tan Y,: A case of intracranial hemorrhage caused by combined dabrafenib and trametinib therapy for metastatic melanoma. Am J Case Rep 2014; 15: 441-443.
9. Furmark L, Pavlick AC,: BRAF Inhibitors and the "Lazarus Syndrome"-An update and perspective. Am J Hematol/Oncol 2015; 11: 24-29.
10. Chapman PB, D'Angelo SP, Wolchok JD,: Rapid eradication of a bulky melanoma mass with one dose of immunotherapy. N Engl J Med 2015; 372: 2073-2074.